Refractory/recurrent B cell source acute lymphocytic leukemia.
Conditions
Interventions
Case series:Cyclophosphamide: intravenous cyclophosphamide 0.8 1.0 g/m ^ 2 / day, infusion 2 days (4 to 5 days prior to cell infusion)
Fluorine dara marina: intravenous fluorine dara marina 25 mg/m ^ 2 / day, infusion three days (3 to 5 days before the cell infusion)
Sponsors
The First Affiliated Hospital of Xinxiang Medical College
Eligibility
Sex/Gender
All
Age
16 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Aged between 16 and 70 years, with a life expectancy of more than 3 months; 2) acute B lymphocytic leukemia diagnosed as CD19+; 3) KPS score >70 points; ZPS score is less than 2; 4) there is no effective treatment after the failure of transplantation of autologous stem cells or allogeneic stem cells, or recurrence after chemotherapy; 5) sufficient heart, liver, kidney, bone marrow function (heart: no heart disease or coronary heart disease, cardiac function: 1-2 level; Liver: total bilirubin is no more than 3 times normal value upper limit (ULN), aspartate aminotransferase (AST) is less than or equal to 2.5; 6) the upper limit of normal value, ALT no more than 2.5 times normal value upper limit; Kidney: Cr = 1.25 times normal value upper limit; Bone marrow: WBC is greater than or equal to 3.0 * 109/L, Hb is greater than 90 g/L, and PLT is greater than 80 * 10^9/L; 7) patients and family members agree to participate in the clinical study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) pregnant or lactating women (women of childbearing age need to have a pregnancy test); 2) serious infectious diseases or viral diseases (HIV positive, syphilis, etc.); 3) active b or c viral hepatitis; non-severe allergic constitution; 4) With other serious diseases (such as autoimmune diseases, immune deficiency and organ transplantation) that conflict with the programme; 5) With history of other malignant tumors; 6) With serious mental disorder; 7) patients who had used a large amount of glucocorticoid or other immunosuppressive agents within 4 weeks; 8) patients with serious heart, liver, renal insufficiency, diabetes and other diseases; 9) transaminase > 2.5 times normal value upper limit, bilirubin > 3 times normal value upper limit, creatinine > 1.25 times normal value upper limit; 10) have participated in other clinical studies in the past 3 months, or have been treated by other gene products; 11) the researcher does not think it is appropriate to participate in the study, or other situations that may affect the analysis of the results of this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tiny residual, The bone marrow; | — |
Countries
China
Contacts
Public ContactJing-Dong Li
the First Affiliated Hospital of Xinxiang Medical College
Outcome results
None listed